| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 5.26 Million |
| Market Size (2030) | USD 7.18 Million |
| CAGR (2025 - 2030) | 6.41 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Animal Ectoparasiticides Market Analysis
The Animal Ectoparasiticides Market size is estimated at USD 5.26 million in 2025, and is expected to reach USD 7.18 million by 2030, at a CAGR of 6.41% during the forecast period (2025-2030).
Key factors driving the market include the rising prevalence of parasitic infections in animals, growing awareness about these infections, and advancements in ectoparasiticide product development. For example, the 2024 Pets in Australia survey revealed that 75% of respondents aged 28-37 own dogs, with two-thirds of respondents from New South Wales and Queensland being dog owners. Additionally, over 42% of respondents aged 58-67 own cats, while nearly 40% of respondents from South Australia reported owning cats. Since dogs and cats are highly susceptible to ectoparasite infections, the demand for ectoparasiticides is expected to increase, thereby driving market growth during the forecast period.
Moreover, the continuous involvement of market players in and regulatory approval of innovative ectoparasiticide products is further likely to drive market growth over the forecast period. For instance, in July 2023, Boehringer Ingelheim received the United States Food and Drug Administration (FDA) approval for the NexGard Brand of Products named NexGard PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets), which is a beef-flavored soft chew that protects dogs from fleas, ticks, heartworm disease, roundworms, and hookworms.
Furthermore, the growing emphasis on awareness campaigns highlighting the significance of treating ectoparasite infestations is contributing to the rising demand for ectoparasiticide products, thereby driving market growth during the forecast period. For instance, in April 2023, the Union Minister for Fisheries, Animal Husbandry, and Dairying launched the Animal Pandemic Preparedness Initiative and World Bank-funded Animal Health System Support for One Health to enhance India's preparedness and response to potential animal pandemics, in line with the One Health approach. This initiative aims to enhance India's preparedness and response to animal pandemics, with a focus on zoonotic diseases that pose a threat to both animal and human health.
Thus, owing to the increase in the adoption of companion animals, the rise in product launches, the presence of parasitic infections among farm animals, and the increase in strategic activities by the key players, the studied market is expected to witness significant growth over the forecast period. However, the high cost of animal healthcare is likely to hinder the market growth over the forecast period.
Animal Ectoparasiticides Market Trends
Dogs Segment is Expected to Witness Positive Growth Over the Forecast Period
Dogs are one of the most commonly adopted companion animals among other categories. The segment is expected to witness significant growth due to the increase in the number of adoptions of dogs in households, the rise in investments towards their healthcare, and the surge in zoonotic and parasitic infections among dogs over the forecast period. According to the American Pet Products Association’s (APPA) 2023-2024 National Pet Owners Survey, the average annual expenditure on dogs amounts to USD 472, significantly higher compared to USD 232 for cats. This higher spending on canine healthcare is expected to drive the adoption of ectoparasiticides, thereby fueling segment growth during the forecast period.
Moreover, the rising number of product launches specifically targeting dog healthcare is anticipated to drive the growth of the studied segment during the forecast period. For instance, in October 2024, Elanco Animal Health received FDA approval for Credelio Quattro, a chewable tablet formulated with lotilaner, moxidectin, praziquantel, and pyrantel. This product delivers comprehensive parasite protection for dogs, targeting six types of parasites, including fleas, ticks, heartworms, roundworms, hookworms, and tapeworms. The approval aligns with the growing demand for effective ectoparasiticides in the canine health market, driven by increasing awareness among pet owners about parasite prevention.
Thus, owing to the increase adoption of dogs in households and the rise in strategic activities by the key players, the studied segment is expected to witness significant growth over the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Witness a Significant Growth Over the Forecast Period
North America is expected to witness significant market growth owing to rising pet adoptions, the increasing per capita animal healthcare expenditure, and the increase in parasitic infections among animals. Furthermore, according to the September 2023 statistics published by the Humane Society, there are over 3,500 animal shelters in the United States. Thus, the growing pet adoption is leading to an increase in focus on pet animal healthcare. Further, due to the availability of pet insurance, pet owners are spending more on pet health care. For instance, as per the the American Pet Products Association’s (APPA), total pet industry expenditures in the United States totaled USD 147 billion in 2023, up 7.5 percent from USD 136.8 billion in 2022. This growth reflects the increasing demand for pet healthcare products, including ectoparasiticides, as pet owners prioritize comprehensive parasite protection for their animals.
Furthermore, the presence of key players and the increase in the launch of veterinary clinics and online veterinary platforms offering veterinary products across the region are expected to bolster the demand for ectoparasiticide over the forecast period. For instance, in March 2024, PetFriendly, a company specializing in pet wellness, unveiled a revamped e-commerce platform, introducing versatile purchasing options for its clientele. While the company previously focused solely on subscription services for personalized flea treatments and wellness products, it identified a growing demand among pet owners for more adaptable and user-friendly pet care solutions. This shift aligns with the increasing demand for ectoparasiticides as pet owners seek effective and convenient ways to protect their pets from external parasites. Thus, owing to such platform launches in the North American region are expected to drive market growth over the forecast period.
Thus, due to the increase in pet insurance cases and the rise in availability of advanced ectoparasitic products, North America is expected to witness significant growth over the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
Animal Ectoparasiticides Industry Overview
The animal ectoparasiticides market is moderately competitive in nature. The key players in the market are primarily focusing on various growth strategies, such as collaborations, partnerships, agreements, mergers, and acquisitions, to enhance their market presence. Some of the major market players include Boehringer Ingelheim, Ceva Animal Health, Inc., Elanco, Merck Animal Health, and Zoetis, among others.
Animal Ectoparasiticides Market Leaders
-
Zoetis Services LLC
-
Elanco
-
Vetoquinol
-
Virbac
-
Boehringer Ingelheim International GmbH
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Animal Ectoparasiticides Market News
- November 2024: Merck Animal Health received the European Commission's approval of the marketing authorization for BRAVECTO TriUNO. This new formulation of BRAVECTO (fluralaner) for dogs addresses both internal and external parasites. The three-in-one chewable tablet will be distributed through licensed veterinarians. Additionally, regulatory agencies in Peru, Guatemala, Nicaragua, and Costa Rica have also approved the product.
- April 2024: Boehringer Ingelheim, introduced NexGard SPECTRA (afoxolaner and milbemycin oxime) in India, following its approval by the Central Drugs Standard Control Organisation (CDSCO). This launch expanded the NexGard portfolio for dogs aged two months and older, weighing two kilograms or more. NexGard SPECTRA is a palatable monthly chew designed to effectively eliminate fleas, ticks, and mites while also addressing gastrointestinal worms.
Animal Ectoparasiticides Industry Segmentation
As per the scope of the report, ectoparasiticides, formulated to eliminate external parasites, are utilized to treat and prevent infestations caused by insects and mites, including fleas, ticks, mosquitoes, sandflies, and biting flies in animals. Product, animal, distribution channel, and geography segment the animal ectoparasiticides market. By product, the market is segmented into pour-on, spray, oral tablet, and others; by animal, the market is segmented into Ruminants, Porcine, Poultry, Dogs, Cats, and Others. By distribution channel, the market is segmented into veterinary clinics, farms, and others. By geography, the market is segmented into North America, Europe, Asia-Pacific, Rest of the World. The report offers the value (in USD) for the above segments.
| By Product | Pour-On | ||
| Spray | |||
| Oral Tablet | |||
| Others | |||
| By Animal | Ruminants | ||
| Porcine | |||
| Poultry | |||
| Dogs | |||
| Cats | |||
| Others | |||
| By Distribution Channel | Veterinary Clinics and Farms | ||
| Others | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Rest of the World | |||
Need A Different Region or Segment?
Customize Now
Animal Ectoparasiticides Market Research Faqs
How big is the Animal Ectoparasiticides Market?
The Animal Ectoparasiticides Market size is expected to reach USD 5.26 million in 2025 and grow at a CAGR of 6.41% to reach USD 7.18 million by 2030.
What is the current Animal Ectoparasiticides Market size?
In 2025, the Animal Ectoparasiticides Market size is expected to reach USD 5.26 million.
Who are the key players in Animal Ectoparasiticides Market?
Zoetis Services LLC, Elanco, Vetoquinol, Virbac and Boehringer Ingelheim International GmbH are the major companies operating in the Animal Ectoparasiticides Market.
Which is the fastest growing region in Animal Ectoparasiticides Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Animal Ectoparasiticides Market?
In 2025, the North America accounts for the largest market share in Animal Ectoparasiticides Market.
What years does this Animal Ectoparasiticides Market cover, and what was the market size in 2024?
In 2024, the Animal Ectoparasiticides Market size was estimated at USD 4.92 million. The report covers the Animal Ectoparasiticides Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Animal Ectoparasiticides Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Animal Ectoparasiticides Industry Report
Statistics for the 2025 Animal Ectoparasiticides market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Animal Ectoparasiticides analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
